Pergolide sulfone
CAS: 72822-03-8
Rif. 3D-FP26841
| 1mg | Fuori produzione | ||
| 2mg | Fuori produzione | ||
| 5mg | Fuori produzione | ||
| 10mg | Fuori produzione | ||
| 25mg | Fuori produzione |
Informazioni sul prodotto
- (8b)-8-[(Methylsulfonyl)methyl]-6-propyl-ergoline
Pergolide sulfone is a prodrug that is converted to its active form, pergolide mesylate, in vivo. Pergolide sulfone has been shown to be active against Parkinson's disease and other disorders of the central nervous system. It has been used for the treatment of Parkinson's disease since 1984. In clinical studies, pergolide sulfone was found to be effective in reducing the symptoms of Parkinson's disease. The most common side effects are nausea and vomiting, which occur in up to 10% of people who take it. Pergolide sulfone binds to dopamine D2 receptors in the striatum and may cause an increase in plasma concentrations of acetylcholine and dopamine by blocking their reuptake into nerve terminals; this leads to increased neurotransmission. The major metabolite formed from pergolide sulfone is a sulfoxide that can be detected by chromatography.br>br>
Pergolide mesylate is
